Isocitrate dehydrogenases (IDH) are central molecular biomarkers of gliomas, which are associated with part of routine histopathological diagnosis, drug sensitivity and prognosis according to the guideline of WHO CNS5 2021 [6]. Here, IDH2 is linked to central nervous system cancer.